ClinicalTrials.gg
Not yet recruitingNCT07613866Updated May 29, 2026

A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria

A Phase 2 interventional study of HRS-3095 Tablet and HRS-3095 Tablet Placebo in Chronic Spontaneous Urticaria, sponsored by Chengdu Suncadia Medicine Co., Ltd.. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Chengdu Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Chronic Urticaria with a site in China — 16 open to participants now, 20 under way, 5 of them phase 3. Chronic Urticaria · China.

Planned enrollment
11th of 30
190 · median 110
Started
2026
with 10 others
Phase 2
7 of 34
6 open now
Primary completion
2026-12
later than 9 of 19 live
Registered
29th of 34
by date
Lead sponsor
2 of 34
Chengdu Suncadia Medicine Co., Ltd.

Among the 34 studies in Chronic Urticaria with a site in China, this one is the 11th largest by planned enrollment of the 30 interventional ones that give a count, is one of 11 that started in 2026, is one of 7 in phase 2, reaches primary completion later than 9 of the 19 other live ones, and was the 29th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

16 of the 34 studies in Chronic Urticaria with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Chronic Urticaria with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy, and safety of HRS-3095 with Chronic Spontaneous in adults, and to explore the reasonable dosage of HRS-3095 for Chronic Spontaneous Urticaria.

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be between 18 and 70 years of age, inclusive, at the time of signing the Form (ICF), with no restriction on gender.
  2. Participants must have a history of chronic spontaneous urticaria (CSU) with a disease duration of at least 6 months prior to screening.
  3. Participants must be diagnosed with H1-antihistamine-inadequately-controlled CSU at screening, defined as: having had persistent symptoms of pruritus and wheals for ≥6 weeks prior to screening, despite regular use of second-generation H1-antihistamines during that period.
  4. At randomization, the UAS7 score must be ≥16 (range: 0-42) and the HSS7 score ≥ 8 (range: 0-21).
  5. Participants must have been on a stable dose of the specified second-generation H1-antihistamine for at least 3 days prior to the first UAS score at screening.
  6. Participants must be willing and able to complete logbook entries as required during the study and must have no missing daily UAS scores during the 7 days before randomization.
  7. Participants must voluntarily sign the Informed Consent Form (ICF) before any study-related procedures, be able to communicate effectively with the investigator, and be willing to strictly adhere to the requirements of the study protocol.
  8. Female participants of or male participants with a female partner of childbearing potential must agree to avoid donating sperm or ova and must agree to take highly effective measures from the time of signing the ICF until 3 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Any skin disease that could interfere with study assessment (e.g., chronic inducible urticaria, urticarial vasculitis, atopic dermatitis, psoriasis).
  2. Use of systemic or topical medications with therapeutic or immunomodulatory effects on the study disease during the relevant prior to screening.
  3. Use of drugs or medical devices within 8 weeks or 5 half-lives (if known), whichever is longer, or within 30 days (for small molecules) prior to screening.
  4. Vaccination or exposure to live or attenuated vaccines within 3 months prior to screening or participation in a vaccine-related clinical trial within 3 months prior to randomization.
  5. History or current coagulation-related risk (e.g., bleeding diathesis, coagulopathy, GI bleeding with clinical significance, antiplatelet or anticoagulant use, history of thrombosis or thromboembolic events, or increased risk of thrombosis).
  6. History of liver disease or current treatment for liver disease (e.g., hepatitis, cirrhosis, liver failure).
  7. History of systemic antimicrobial use or presence of superficial skin infection (e.g., impetigo) within 4 weeks prior to screening.
  8. History of or current malignancy (excluding completely resected and recurrence-free basal cell carcinoma, squamous cell carcinoma, or cervical intraepithelial neoplasia).
  9. Major surgery performed within 3 months prior to randomization or planned during the study.
  10. Serious concomitant disease or any condition judged by the investigator to make the participant unsuitable for study participation.
  11. Abnormal findings in vital signs, physical examination, laboratory tests, , chest X-ray/CT, or abdominal ultrasound during screening that have clinical significance and may affect study validity or participant safety.
  12. Pregnant or breastfeeding women.
  13. Allergy to the study drug or any of its components.
  14. History of alcohol abuse within 6 months prior to screening (e.g., > 14 units/week) or history of illicit drug abuse within 6 months prior to screening.
  15. Any condition judged by the investigator that may affect the safety or efficacy evaluation of the study drug or participant compliance with the study procedures or diary.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
190 participants (estimated)

Study arms

  • Experimental
    HRS-3095 Group

    HRS-3095 in different doses.

    Drug: HRS-3095 Tablet

  • Placebo comparator
    HRS-3095 placebo Group

    HRS-3095 blank preparation.

    Drug: HRS-3095 Tablet Placebo

Interventions

  • HRS-3095 tablet.

  • DrugHRS-3095 Tablet Placebo

    HRS-3095 tablet placebo.

06

What researchers measure

Primary outcomes

  1. Change in Weekly Urticaria Activity Score (UAS7) from baseline at Week 4.

    Time frame: Up to 4 weeks.

Secondary outcomes

  1. The concentration of HRS-3095 in serum (Cmax)

    Time frame: From the beginning of administration to the 4th week.

  2. The time of metabolism of the drug in the serum

    The concentration of HRS-3095 in plasma will be determined.

    Time frame: From the beginning of administration to the 4th week.

  3. The concentration of HRS-3095 in serum (AUC)

    The concentration of HRS-3095 in plasma will be determined.

    Time frame: From the beginning of administration to the 4th week.

  4. Change in Weekly Urticaria Activity Score (UAS7) from baseline at Week 2

    Time frame: Up to 4 weeks.

  5. Change in Weekly Itch Severity Score (ISS7) from baseline at Week 2 and 4

    Time frame: Up to 4 weeks.

  6. Change in Weekly Wheal Severity Score (HSS7) from baseline at Week 2 and 4

    Time frame: Up to 4 weeks.

  7. Percentage change in Weekly Urticaria Activity Score (UAS7) from baseline at Week 2 and 4

    Time frame: Up to 4 weeks.

  8. Percentage change in Weekly Itch Severity Score (ISS7) from baseline at Week 2 and 4

    Time frame: Up to 4 weeks.

  9. Percentage change in Weekly Wheal Severity Score (HSS7) from baseline at Week 2 and 4

    Time frame: Up to 4 weeks.

  10. Proportion of patients with UAS7 ≤ 6 at Week 2 and 4 compared to baseline

    Time frame: Up to 4 weeks.

  11. Proportion of patients with UAS7 = 0 at Week 2 and 4 compared to baseline

    Time frame: Up to 4 weeks.

  12. Proportion of patients achieving the Minimum Important Difference (MID) in UAS7 at Week 2 and 4

    ≥ 10-point decrease from baseline.

    Time frame: Up to 4 weeks.

  13. Proportion of patients achieving the Minimum Important Difference (MID) in ISS7 at Week 2 and 4

    ≥ 5-point decrease from baseline.

    Time frame: Up to 4 weeks.

  14. Time to achieve the Minimum Important Difference (MID) in UAS7

    ≥ 10-point decrease from baseline.

    Time frame: Up to 4 weeks.

  15. Time to achieve the Minimum Important Difference (MID) in ISS7

    ≥ 10-point decrease from baseline.

    Time frame: Up to 4 weeks.

  16. Change in 7-day Angioedema Activity Score (AAS7) from baseline at Week 2 and 4

    Time frame: Up to 4 weeks.

  17. Change in Urticaria Control Test (UCT) from baseline at Week 4

    Time frame: Up to 4 weeks.

  18. Proportion of participants with UCT ≥ 12 at Week 4 compared to baseline

    Time frame: Up to 4 weeks.

  19. Change in Dermatology Life Quality Index (DLQI) from baseline at Week 4

    Time frame: Up to 4 weeks.

  20. Proportion of participants with DLQI = 0 or 1 at Week 4 compared to baseline

    Time frame: Up to 4 weeks.

  21. Adverse events

    Time frame: From the beginning of administration to the 8th week.

  22. Plasma concentrations of HRS-3095 and its metabolites

    Time frame: From the beginning of administration to the 4th week.

  23. Relative change from baseline in serum total immunoglobulin E (IgE)

    Time frame: From the beginning of administration to the 4th week.

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Dec 2026, 5 months later.

Of 31 phase 2 interventional studies under Chronic Urticaria, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
May 29, 2026
StartEst.
Jul 2026
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07613866
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Jul 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
May 29, 2026

Study contacts

Yijia Xu
Contact
yijia.xu@hengrui.com
+86-0518-81220121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-3095

Start the discussion